Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives

Background: Surgery still represents the gold standard of treatment for resectable pancreatic ductal adenocarcinoma (PDAC). Neoadjuvant treatments (NAT), currently proposed for borderline and locally advanced PDACs, are gaining momentum even in resectable tumors due to the recent interesting concept...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppola, Alessandro, La Vaccara, Vincenzo, Farolfi, Tommaso, Fiore, Michele, Cammarata, Roberto, Ramella, Sara, Coppola, Roberto, Caputo, Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495897/
https://www.ncbi.nlm.nih.gov/pubmed/36140192
http://dx.doi.org/10.3390/biomedicines10092091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495897/
https://www.ncbi.nlm.nih.gov/pubmed/36140192
http://dx.doi.org/10.3390/biomedicines10092091

Ejemplares similares